Last week, shares of these three biotech stocks rocketed higher, but their market values are still relatively small. Here's what you need to know about the businesses behind these recent stock market run-ups before thinking about adding them to a portfolio you'd like to manage successfully.

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present at two upcoming virtual healthcare investor conferences.

Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, or the Company, together with its development and commercialization partner Chiesi Global Rare Diseases, a unit of Chiesi, an international research-focused healthcare group, today announced the submission on May 27, 2020 of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for pegunigalsidase alfa for the proposed treatment of adult patients with Fabry disease via the FDA's Accelerated Approval pathway. Pegunigalsidase alfa, or PRX-102, was granted Fast Track designation by the FDA in January 2018. Pegunigalsidase alfa is the Company's purposefully-designed, long-acting recombinant, PEGylated, cross-linked α-galactosidase-A investigational product candidate.

The latest analyst coverage could presage a bad day for Protagonist Therapeutics, Inc. (NASDAQ:PTGX), with the...

The investors in Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) will be rubbing their hands together with glee today...

Whilst it may not be a huge deal, we thought it was good to see that the Protagonist Therapeutics, Inc. (NASDAQ:PTGX...

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced initial data from the ongoing Phase 2 study of PTG-300 in patients with polycythemia vera. The current results demonstrate that treatment with PTG-300 at individualized doses ranging from 10 mg to 80 mg for up to 28 weeks provided dose-related control of hematocrit levels and eliminated the need for phlebotomy in all six out of six patients that received the dosing as per protocol. A seventh patient with 12 weeks of treatment had an unintended dose interruption, received a single phlebotomy, and remains on the study. In addition, positive symptomatic measurements related to the ability of PTG-300 to address iron deficiency in these frequently phlebotomized patients were observed, with increases in serum ferritin values approaching the range observed in healthy subjects. Patients enrolled in the current study had received at least three phlebotomies within a 24 week period prior to PTG-300 treatment and were treated for up to 28 weeks as of the cutoff date of May 1, 2020 (range of 4 to 28 weeks, n=7 evaluable for efficacy). Enrollment in the study continues and a total of eight patients have enrolled to date.

Q4 2019 Protagonist Therapeutics Inc Earnings Call

Image source: The Motley Fool. Protagonist Therapeutics, Inc. Common Stock (NASDAQ: PTGX)Q1 2020 Earnings CallMay 07, 2020, 5:00 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood day, and welcome to the Protagonist Therapeutics PTG-300 development update Call.

Shares of Protagonist Therapeutics (NASDAQ: PTGX) -- a clinical-stage biopharmaceutical company -- are up by 111.6% as of 12:34 p.m. EDT on Friday. Protagonist Therapeutics released its fiscal first-quarter earnings report after the market closed on Thursday, and the company announced some exciting news regarding one of its most promising pipeline candidates, PTG-300. In its quarterly update, Protagonist Therapeutics announced that it had chosen polycythemia vera -- a rare type of blood cancer that leads to an abnormal level of red blood cells -- as the first indication for which to run a pivotal study for PTG-300.

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported its financial results for the first quarter ended March 31, 2020, and provided an update on clinical development programs.

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on April 15, 2020, it issued an inducement award to Tracy Woody, the Company's recently hired Executive Vice President of Corporate Strategy, in accordance with the terms of Ms. Woody's employment offer letter. The award was granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020.

In 2008, Dinesh Patel was appointed CEO of Protagonist Therapeutics, Inc. (NASDAQ:PTGX). First, this article will...

Q1 2020 Protagonist Therapeutics Inc Earnings Call

In the current session, Protagonist Therapeutics Inc. (NASDAQ: PTGX) is trading at $12.04, after a 55.7% increase. Over the past month, the stock increased by 72.49%, and in the past year, by 15.33%. With performance like this, long-term shareholders optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.Assuming that all other factors are held constant, this could present itself as an opportunity for shareholders trying to capitalize on the higher share price. The stock is currently down from its 52 week high by 27.77%.The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against its past earnings, historical data and aggregate market data for the industry or the indices, such as S&P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also shows that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future.Most often, an industry will prevail in a particular phase of a business cycle, than other industries.Protagonist Therapeutics has a lower P/E than the aggregate P/E of 0.1 of the biotechnology industry. Ideally, one might believe that they might perform worse than its peers, but it's also probable that the stock is undervalued.There are many limitations to P/E ratio. It is sometimes difficult to determine the nature of the earnings makeup of a company. Shareholders might not get what they're looking for, from trailing earnings.See more from Benzinga * Recap: Dentsply Sirona Q1 Earnings * Recap: Pinnacle West Capital Q1 Earnings * Lear: Q1 Earnings Insights(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Companies In The News Are: FTEK, PTGX, SXC, ZG

Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a clinical stage biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 7,000,000 shares of its common stock at a price to the public of $14.00 per share. The offering was upsized from the previously announced 5,000,000 shares. Gross proceeds to Protagonist from the offering are expected to be $98.0 million, before deducting underwriting discounts and commissions and estimated offering expenses. All of the shares of common stock are being offered by Protagonist. In addition, Protagonist has granted the underwriters a 30-day option to purchase up to 1,050,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about May 14, 2020, subject to satisfaction of customary closing conditions.

Shares of micro-cap biopharmaceutical company Protagonist Therapeutics (PTGX) soared on Friday, and were up over 90% at one point in afternoon trading.

One thing we could say about the analysts on Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - they aren't optimistic...

Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of 5,000,000 shares of its common stock. All of the shares of common stock are being offered by Protagonist. In connection with this offering, Protagonist expects to grant the underwriters a 30-day option to purchase up to 750,000 additional shares of common stock.